16
Aug
2017
Tag: combination therapy
20
Jun
2017
Bionest
ASCO 2017 — Some Take-Aways
Several members of the Bionest team attended ASCO this year — the biggest cancer conference in the world, attracting over 30,000 oncology researchers, biopharmaceutical executives, public health experts, investors and journalists. As we predicted in our pre-ASCO post, one of the biggest take-aways from the conference was the continued and ever-growing emphasis on combination...
26
May
2017
Bionest
It’s ASCO Time Once Again!
ASCO is the largest annual gathering of the worldwide oncology community, and this year’s event takes place this coming weekend, from June 2-6 in Chicago, Illinois. About 10 days ago, the association released its program and a wide slate of abstracts that have given way to plenty of media reports and speculation about what other...
5
Apr
2017
Bionest
PARP Inhibitors Chalk Up Impressive Gains in Ovarian Cancer Maintenance Therapy
On March 27, the FDA gave Tesaro a broad approval for its PARP inhibitor, niraparib, as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy. The FDA decision came well in advance of the PDUFA date set for June 30, and...
29
Sep
2016
Bionest
Blue Ribbon Panel Issues Cancer Moonshot Recommendations
On September 7, a Blue Ribbon Panel — composed of 28 top cancer researchers, oncologists, patient advocates and leaders from the private sector — issued 10 recommendations aimed at speeding up advances in cancer prevention, diagnosis, treatment and care. The panel was created as part of the Cancer Moonshot first announced in January of this...
16
Aug
2016
Bionest
Running the Risks of High Stakes Drug Development
On August 5, Bristol-Myers Squibb (BMS) surprised many with the announcement that their PD-L1 inhibitor Opdivo® (nivolumab) had failed a Phase 3 trial assessing its use as a monotherapy in the first-line treatment of non-small cell lung cancer (NSCLC). This is a disease where the drug is already approved and used in patients who have failed prior...
6
Jul
2016
Bionest
Collective Wisdom Around Oncology – Comments on ASCO 2016
The Bionest Oncology team spent a jam packed and exciting five days at ASCO 2016 earlier this month in Chicago. More than 30,000 oncology professionals gathered from all around the world to discuss the latest data and innovations in oncology, and it did not disappoint. The theme of ASCO this year was Collective Wisdom, which...
31
Mar
2016
Bionest
“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies
The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...
16
Mar
2016
Bionest
Making a “Moonshot” Against Cancer
President Obama, in his 2016 State of the Union Address, called on Vice President Biden to lead a new national “Moonshot” to “eliminate cancer as we know it.” The White House has since announced a billion dollar initiative — inspired by recent successes in the areas of cancer immunotherapy and multi-drug combinations — to jump-start this...
15
Dec
2015